Enzolytics, Inc. ENZC
Set alert
0.00 USD 0.00 0.00%
At close · Oct 30
0.0004 Day range 0.0004
0.0002 52-week range 0.0013
- YTD
- +33.33%
- 1 year
- +14.29%
- Open
- 0.0004
- Prev close
- 0.0004
- Mkt cap
- 1.93M
- Vol
- 12.66K
- Avg vol
- 3.58M
- EPS
- -0.34
- P/E
- 0.00
More statistics
- Low
- 0.0004
- High
- 0.0004
3M chart
Signals (21)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 27, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 27, 2026 | 5 days ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 25, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 22, 2026 | 1 month ago |
| RSI: Oversold | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| RSI: Oversold | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| RSI: Oversold | Aug 6, 2026 | 2 months ago |
News
- Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
- Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
- Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
- Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
- Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
- Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
- Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
- Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
- Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment
- Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.
Your note
Sign in to keep a note on ENZC — it syncs with the Stock Master app.